The government of President Claudia Sheinbaum has announced a historic investment of more than 21 billion pesos from pharmaceutical companies to strengthen Mexico’s health sector, focusing on medicine production, research, and industrial development.
Key Announcements
- Total Investment: Over 21 billion pesos from leading pharmaceutical firms.
- Objective: Boost national medicine manufacturing, expand research capacity, and consolidate Mexico’s industrial health infrastructure.
- Plan: Part of the broader Plan México, aimed at ensuring sovereignty in health and reducing dependence on imports.
Major Projects
- Abbott: 3.5 billion pesos, creating 1,200 direct jobs by 2030.
- Bristol Myers Squibb: 1 billion pesos, generating 380 direct jobs and reinforcing sovereignty in drug supply.
- Grupo Neolpharma: 750 million pesos, with 250 direct and 900 indirect jobs.
- Opella: 2.3 billion pesos for expanded production.
- Laboratorios Kener: 5.36 billion pesos to increase manufacturing capacity.
- Liomont: 4 billion pesos investment.
- Sanofi: Project to produce insulin and transfer technology, ensuring full coverage for patients requiring treatment.
- Bayer México: 150 million pesos for clinical studies.
Government Perspective
- David Kershenobich, Secretary of Health, emphasized that the investment represents more than financial growth—it is a chance to consolidate Mexico’s pharmaceutical industry.
- President Claudia Sheinbaum highlighted the international collaboration, including ties with the European Investment Bank, and stressed the importance of innovation, such as mRNA vaccine production.
This investment marks a turning point for Mexico’s health sector, promising job creation, technological advancement, and greater access to essential medicines. It also reflects Sheinbaum’s commitment to strengthening national sovereignty in healthcare while fostering international cooperation.
The 21 billion peso investment by pharmaceutical companies will transform Mexico’s medical industry, creating thousands of jobs and ensuring wider access to life-saving treatments.
Source: Vanguardia
